AP3441A - Pharmaceutical compositions comprising hydromorphone and naloxone - Google Patents

Pharmaceutical compositions comprising hydromorphone and naloxone

Info

Publication number: AP3441A
Authority: AP; ARIPO
Prior art keywords: hydromorphone; naloxone; pharmaceutical compositions; pharmaceutical; compositions
Prior art date: 2010-05-10

Application number

AP2012006606A

Other languages

English (en)

Other versions

AP2012006606A0 (en

Inventor

Malcolm Walden

Jonathon Oliver Whitehouse

Geoffrey Gerard Hayes

Original Assignee

Euro Celtique Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-05-10

Filing date

2011-05-10

Publication date

2015-10-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42983574&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP3441(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-05-10 Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa

2012-12-31 Publication of AP2012006606A0 publication Critical patent/AP2012006606A0/xx

2015-10-31 Application granted granted Critical

2015-10-31 Publication of AP3441A publication Critical patent/AP3441A/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

AP2012006606A 2010-05-10 2011-05-10 Pharmaceutical compositions comprising hydromorphone and naloxone AP3441A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP10162428		2010-05-10
PCT/EP2011/057566 WO2011141488A2 (en)	2010-05-10	2011-05-10	Pharmaceutical compositions comprising hydromorphone and naloxone

Publications (2)

Publication Number	Publication Date
AP2012006606A0 AP2012006606A0 (en)	2012-12-31
AP3441A true AP3441A (en)	2015-10-31

Family

ID=42983574

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AP2012006606A AP3441A (en)	2010-05-10	2011-05-10	Pharmaceutical compositions comprising hydromorphone and naloxone

Country Status (35)

Country	Link
US (1)	US9700508B2 (ja)
EP (1)	EP2568967B2 (ja)
JP (1)	JP5671609B2 (ja)
KR (2)	KR101858797B1 (ja)
CN (2)	CN102946870A (ja)
AP (1)	AP3441A (ja)
AR (1)	AR083150A1 (ja)
AU (1)	AU2011252039B2 (ja)
BR (1)	BR112012028773A2 (ja)
CA (1)	CA2739751C (ja)
CH (1)	CH705273B1 (ja)
CL (1)	CL2012003012A1 (ja)
CO (1)	CO6640216A2 (ja)
CR (1)	CR20120549A (ja)
DE (1)	DE112011101605T5 (ja)
DK (1)	DK178741B1 (ja)
EA (1)	EA201291211A1 (ja)
EC (1)	ECSP12012236A (ja)
ES (1)	ES2408343B2 (ja)
GB (1)	GB2492037A (ja)
GT (1)	GT201200304A (ja)
IL (1)	IL222772B (ja)
MX (1)	MX347105B (ja)
MY (1)	MY157673A (ja)
NI (1)	NI201200157A (ja)
NO (1)	NO20121414A1 (ja)
NZ (2)	NZ700732A (ja)
PE (1)	PE20130657A1 (ja)
SE (1)	SE1251371A1 (ja)
SG (1)	SG184523A1 (ja)
TN (1)	TN2012000488A1 (ja)
TW (2)	TWI590835B (ja)
UA (1)	UA106278C2 (ja)
WO (1)	WO2011141488A2 (ja)
ZA (1)	ZA201207603B (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN103002882B (zh)	2010-05-10	2016-03-02	欧洲凯尔特公司	不含活性剂之颗粒及包含其之片剂的制备
CA2739751C (en)	2010-05-10	2014-08-12	Euro-Celtique, S.A.	Pharmaceutical compositions comprising hydromorphone and naloxone
WO2011141490A1 (en)	2010-05-10	2011-11-17	Euro-Celtique S.A.	Combination of active loaded granules with additional actives
CA2883077C (en) *	2012-09-03	2017-03-07	Daiichi Sankyo Company, Limited	Hydromorphone hydrochloride-containing oral sustained-release pharmaceutical composition
CA2881144A1 (en) *	2012-11-09	2014-05-09	Purdue Pharma	Pharmaceutical compositions comprising hydromorphone and naloxone
US9517208B2 (en) *	2013-03-15	2016-12-13	Purdue Pharma L.P.	Abuse-deterrent dosage forms
GB201313915D0 (en)	2013-08-02	2013-09-18	Johnson Matthey Plc	Process
CA2929909C (en) *	2013-11-13	2018-08-21	Euro-Celtique S.A.	Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
CA2847781C (en) *	2014-03-28	2019-03-12	Purdue Pharma	Reducing drug liking in a subject
WO2016091805A2 (de) *	2014-12-08	2016-06-16	Develco Pharma Schweiz Ag	Naloxon-monopräparat und mehrschichttablette
WO2021163252A1 (en) *	2020-02-14	2021-08-19	Teikoku Pharma Usa, Inc.	Topical naloxone compositions and methods for using the same

Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4457933A (en) *	1980-01-24	1984-07-03	Bristol-Myers Company	Prevention of analgesic abuse
WO2003013525A1 (en) *	2001-08-06	2003-02-20	Euro-Celtique S.A.	Opioid agonist formulations with releasable and sequestered antagonist
US20060039970A1 (en) *	2000-02-08	2006-02-23	Benjamin Oshlack	Tamper-resistant oral opioid agonist formulations
US20070014732A1 (en) *	2001-08-06	2007-01-18	Purdue Pharma L.P.	Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant agent
WO2010140007A2 (en) *	2009-06-05	2010-12-09	Euro-Celtique S.A.	Dosage form

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE49324B1 (en)	1979-12-19	1985-09-18	Euro Celtique Sa	Controlled release compositions
HU190619B (en)	1983-11-11	1986-09-29	Bezzegh,Denes,Hu	Process for producing tablets with controlled dissolution of active ingredients
EP0164669B1 (de)	1984-06-13	1991-01-23	Röhm Gmbh	Verfahren zum Überziehen von Arzneiformen
US4769372A (en) *	1986-06-18	1988-09-06	The Rockefeller University	Method of treating patients suffering from chronic pain or chronic cough
GB8626098D0 (en)	1986-10-31	1986-12-03	Euro Celtique Sa	Controlled release hydromorphone composition
EP0352361A1 (en)	1988-07-29	1990-01-31	The Rockefeller University	Method of treating patients suffering from chronic pain or chronic cough
FR2653337B1 (fr)	1989-10-23	1992-02-07	Dow Corning Sa	Element a liberation prolongee et procede pour le fabriquer.
US5662933A (en)	1993-09-09	1997-09-02	Edward Mendell Co., Inc.	Controlled release formulation (albuterol)
US5965161A (en)	1994-11-04	1999-10-12	Euro-Celtique, S.A.	Extruded multi-particulates
DE4443105C2 (de)	1994-12-03	1997-03-13	Hoechst Ag	Verfahren zur Herstellung Molsidomin-haltiger Tabletten
US6488961B1 (en)	1996-09-20	2002-12-03	Ethypharm, Inc.	Effervescent granules and methods for their preparation
DE19651551C2 (de) *	1996-12-11	2000-02-03	Klinge Co Chem Pharm Fab	Opioidantagonisthaltige galenische Formulierung
US6306438B1 (en)	1997-07-02	2001-10-23	Euro-Celtique, S.A.	Stabilized sustained release tramadol formulations
ATE323491T1 (de)	1997-12-22	2006-05-15	Euro Celtique Sa	Peroral zu verabreichende arzneiform enthaltend eine kombination von einem opioid agonisten und naltrexon
ECSP003314A (es)	2000-01-11	2000-03-22		Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide y un - agonista
US6716449B2 (en)	2000-02-08	2004-04-06	Euro-Celtique S.A.	Controlled-release compositions containing opioid agonist and antagonist
US20040115133A1 (en)	2000-05-10	2004-06-17	Wermeling Daniel P.	Intranasal opioid compositions
GB0102342D0 (en)	2001-01-30	2001-03-14	Smithkline Beecham Plc	Pharmaceutical formulation
US20030065002A1 (en) *	2001-05-11	2003-04-03	Endo Pharmaceuticals, Inc.	Abuse-resistant controlled-release opioid dosage form
ES2275868T3 (es) *	2001-05-11	2007-06-16	Endo Pharmaceuticals Inc.	Forma de dosificacion de opioide para impedir el consumo abusivo.
CN100356907C (zh)	2001-06-08	2007-12-26	恩德制药公司	利用丙烯酸酯聚合物的控释剂型和其制备方法
MXPA04001208A (es)	2001-08-06	2004-07-08	Euro Celtique Sa	Composiciones y metodos para evitar el abuso de los opioides.
NZ531152A (en)	2001-08-23	2005-11-25	Akzo Nobel Nv	Process for the preparation of a 14 hydroxynormorphinone derivative
DE10146275A1 (de)	2001-09-18	2003-04-24	Gruenenthal Gmbh	Kombination ausgewählter Opioide mit Muscarin-Antagonisten zur Therapie der Harninkontinenz
AU2003224040B2 (en)	2002-04-05	2006-06-22	Mundipharma Pty Limited	Pharmaceutical preparation containing oxycodone and naloxone
DE10215131A1 (de) *	2002-04-05	2003-10-16	Euro Celtique Sa	Matrix zur verzögerten, gleichbleibenden und unabhängigen Freisetzung von Wirkstoffen
NZ536975A (en)	2002-07-04	2006-10-27	Janssen Pharmaceutica Nv	Solid dispersions of a poorly soluble bioactive compound comprising two different polymer matrixes
WO2004091665A1 (en)	2003-04-08	2004-10-28	Progenics Pharmaceuticals, Inc.	Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
PL2368553T3 (pl)	2003-04-08	2015-05-29	Progenics Pharm Inc	Preparaty farmaceutyczne zawierające metylonaltrekson
CA2521369A1 (en)	2003-04-08	2004-10-28	Progenics Pharmaceuticals, Inc.	The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
RS20050812A (en)	2003-04-30	2007-12-31	Purdue Pharma L.P.,	Tamper resistant transdermal dosage form
US9114199B2 (en)	2003-07-31	2015-08-25	Boston Scientific Scimed, Inc.	Implantable or insertable medical devices containing acrylic copolymer for controlled delivery of therapeutic agent
US20050079221A1 (en)	2003-10-10	2005-04-14	Groenewoud Pieter Jurjen	Ibuprofen narcotic composition and method for making same
US20050232987A1 (en)	2004-03-12	2005-10-20	Viswanathan Srinivasan	Dosage form containing a morphine derivative and another drug
US20050165038A1 (en)	2004-01-22	2005-07-28	Maxwell Gordon	Analgetic dosage forms that are resistant to parenteral and inhalation dosing and have reduced side effects
US8003793B2 (en)	2004-02-06	2011-08-23	Purdue Pharma L.P.	Methods for making 3-O-protected morphinones and 3-O-protected morphinone dienol carboxylates
TWI350762B (en)	2004-02-12	2011-10-21	Euro Celtique Sa	Particulates
US9016221B2 (en)	2004-02-17	2015-04-28	University Of Florida Research Foundation, Inc.	Surface topographies for non-toxic bioadhesion control
TWI365880B (en)	2004-03-30	2012-06-11	Euro Celtique Sa	Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp
US7700626B2 (en)	2004-06-04	2010-04-20	Adolor Corporation	Compositions containing opioid antagonists
EP1604667A1 (en)	2004-06-08	2005-12-14	Euro-Celtique S.A.	Opioids for the treatment of the restless leg syndrome
EP1604666A1 (en)	2004-06-08	2005-12-14	Euro-Celtique S.A.	Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
GB2418854B (en)	2004-08-31	2009-12-23	Euro Celtique Sa	Multiparticulates
US20060088594A1 (en)	2004-10-08	2006-04-27	Pilgaonkar Pratibha S	Highly compressible controlled delivery compositions of metformin
GB0423103D0 (en)	2004-10-19	2004-11-17	Boots Healthcare Int Ltd	Therapeutic agents
MX2007008756A (es)	2005-01-20	2007-09-27	Progenics Pharm Inc	Uso de metilnaltrexona y compuestos relacionados para el tratamiento de disfuncion gastrointestinal postoperatoria.
CA2594373A1 (en) *	2005-01-28	2006-08-03	Euro-Celtique S.A.	Alcohol resistant dosage forms
EP1695700A1 (en)	2005-02-28	2006-08-30	Euro-Celtique S.A.	Dosage form containing oxycodone and naloxone
NL1028460C2 (nl) *	2005-03-04	2006-09-06	Sara Lee De Nv	Inrichting voor het bereiden en afgeven van al dan niet althans gedeeltelijk opgeschuimde dranken.
JP4741865B2 (ja)	2005-03-24	2011-08-10	共和薬品工業株式会社	ペルゴリド錠剤の製造方法
US20070026025A1 (en)	2005-04-12	2007-02-01	Aquegel Cosmetics, Llc	Topical ointment and method for making and using same
TWI366460B (en)	2005-06-16	2012-06-21	Euro Celtique Sa	Cannabinoid active pharmaceutical ingredient for improved dosage forms
WO2007013047A2 (en)	2005-07-29	2007-02-01	Ranbaxy Laboratories Limited	Water-dispersible anti-retroviral pharmaceutical compositions
US20070048364A1 (en)	2005-08-04	2007-03-01	Yingxu Peng	Free flowing granules containing carbomer
DE102005047561A1 (de)	2005-10-04	2007-04-05	Bayer Healthcare Ag	Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
RU2435592C2 (ru)	2005-12-14	2011-12-10	Ф.Хоффманн-Ля Рош Аг	Композиция пролекарства для борьбы с вирусом гепатита с
US20070141147A1 (en)	2005-12-21	2007-06-21	Auriga Laboratories, Inc.	Sequential release pharmaceutical formulations
EP1813276A1 (en)	2006-01-27	2007-08-01	Euro-Celtique S.A.	Tamper resistant dosage forms
US7799790B2 (en)	2006-07-20	2010-09-21	Helm Ag	Amorphous aripiprazole and process for the preparation thereof
SA07280459B1 (ar)	2006-08-25	2011-07-20	بيورديو فارما إل. بي.	أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102006051020A1 (de)	2006-10-26	2008-04-30	Evonik Röhm Gmbh	Verwendung von (Meth)acrylat-Copolymeren in Retard-Arzneiformen zur Verringerung des Einflusses von Ethanol auf die Wirkstofffreisetzung
GB2447898B (en)	2007-03-24	2011-08-17	Reckitt Benckiser Healthcare	A tablet having improved stability with at least two actives
PT2379066E (pt)	2008-09-16	2014-07-04	Imuneks Farma Ilaç Sanayi Ve Ticaret A S	Uso de antagonistas opioides para a preparação de um medicamento no tratamento das doenças degenerativas da retina
US20110165248A1 (en)	2008-09-18	2011-07-07	Meridith Lee Machonis	Pharmaceutical dosage forms comprising poly(e-caprolactone)
PL2326313T3 (pl)	2008-09-24	2015-08-31	Evonik Roehm Gmbh	Kompozycja farmaceutyczna o zależnym od pH kontrolowanym uwalnianiu dla nieopioidów z odpornością przed wpływem etanolu
PL2341899T3 (pl)	2008-09-24	2015-05-29	Evonik Roehm Gmbh	Opioidowa kompozycja farmaceutyczna o zależnym od pH kontrolowanym uwalnianiu z odpornością na działanie etanolu
LT2352494T (lt)	2008-10-30	2019-11-11	Gruenenthal Gmbh	Naujos ir stiprios tapentadolio vaisto formos
US20100143486A1 (en)	2008-12-10	2010-06-10	Nipun Davar	Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same
BRPI0923836A2 (pt)	2008-12-31	2015-07-21	Upsher Smith Lab Inc	Composições farmacêuticas orais contendo opióide e métodos
WO2010081034A2 (en)	2009-01-09	2010-07-15	President And Fellows Of Harvard College	Fluorine containing compounds and methods of use thereof
AU2010206724A1 (en)	2009-01-22	2011-07-28	Nanotherapeutics, Inc.	Process for preparing particles of opioids and compositions produced thereby
EP3184105A1 (en)	2009-02-06	2017-06-28	Egalet Ltd.	Pharmaceutical compositions resistant to abuse
JP5778042B2 (ja)	2009-02-17	2015-09-16	マリンクロッドエルエルシー	ノルモルフィナンの還元的アルキル化のためのプロセス
EP2398805A1 (en)	2009-02-23	2011-12-28	Mallinckrodt LLC	(+)-morphinanium quaternary salts and processes for their production
US8563727B2 (en)	2009-02-23	2013-10-22	Mallinckrodt Llc	(+)-morphinanium N-oxides and processes for their production
US20100227876A1 (en)	2009-03-06	2010-09-09	Rechfensen Llp	Methods of Reducing Side Effects of Analgesics
BRPI1006186A2 (pt)	2009-03-10	2016-08-23	Euro Celtique Sa	composições farmaceuticas de liberação imediata compreedendo oxicodona e naloxona
MX2011009669A (es)	2009-03-18	2011-12-14	Evonik Roehm Gmbh	Composición farmacéutica de liberación controlada con resistencia a la influencia de etanol mediante un revestimiento compuesto de una mezcla polimérica y excipientes.
CN102355893A (zh)	2009-03-18	2012-02-15	赢创罗姆有限公司	采用含有中性乙烯基聚合物和赋形剂的包衣的具有耐乙醇影响的控释药物组合物
AU2010231126A1 (en)	2009-04-02	2011-10-13	Shire Llc	Novel dicarboxylic acid linked amino acid and peptide prodrugs of opioids and uses thereof
US20120065179A1 (en)	2009-04-14	2012-03-15	YKI, Ytemiska Institutet AB	Prodrug comprising beta-keto carboxylic acid, beta-keto carboxylic acid salt or beta-keto carboxylic acid ester for drug delivery
US20100291151A1 (en)	2009-04-21	2010-11-18	Auspex Pharmaceuticals, Inc.	1-methylpyrazole modulators of substance p, calcitonin gene-related peptide, adrenergic receptor, and/or 5-ht receptor
WO2010121620A1 (en)	2009-04-24	2010-10-28	Fertin Pharma A/S	Particulate material for controlled release of active ingredients
WO2010141505A1 (en)	2009-06-01	2010-12-09	Protect Pharmaceutical Corporation	Abuse-resistant delivery systems
PL2440562T3 (pl)	2009-06-11	2017-07-31	Mallinckrodt Llc	Otrzymywanie 6-alfa-amino-N-podstawionych morfinanów w wyniku katalitycznego przeniesienia wodoru
FR2946533A1 (fr)	2009-06-12	2010-12-17	Ethypharm Sa	Reduction des fluctuations plasmatiques d'opioides.
US8829020B2 (en)	2009-07-16	2014-09-09	Mallinckrodt Llc	Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
JP5667183B2 (ja)	2009-07-22	2015-02-12	グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング	加熱溶融押出成型した制御放出性投与剤型
EP2662076A1 (en)	2009-07-22	2013-11-13	Grünenthal GmbH	Oxidation-stabilized tamper-resistant dosage form
GB0914338D0 (en)	2009-08-17	2009-09-30	Johnson Matthey Plc	Improved process
RU2600736C2 (ru)	2009-09-08	2016-10-27	Сигничер Терапьютикс, Инк.	Композиции, содержащие расщепляемые ферментами опиоидные пролекарства с модифицированным кетоном и их дополнительные ингибиторы
EP3064064A1 (en)	2009-09-30	2016-09-07	Acura Pharmaceuticals, Inc.	Methods and compositions for deterring abuse
WO2011041470A2 (en)	2009-09-30	2011-04-07	Mallinckrodt Inc.	Sustained-release opiate and opiate derivative compositions
WO2011141490A1 (en)	2010-05-10	2011-11-17	Euro-Celtique S.A.	Combination of active loaded granules with additional actives
CN103002882B (zh)	2010-05-10	2016-03-02	欧洲凯尔特公司	不含活性剂之颗粒及包含其之片剂的制备
CA2739751C (en)	2010-05-10	2014-08-12	Euro-Celtique, S.A.	Pharmaceutical compositions comprising hydromorphone and naloxone
GB201020895D0 (en)	2010-12-09	2011-01-26	Euro Celtique Sa	Dosage form

2011
- 2011-05-10 CA CA2739751A patent/CA2739751C/en not_active Expired - Fee Related
- 2011-05-10 JP JP2013509554A patent/JP5671609B2/ja not_active Expired - Fee Related
- 2011-05-10 NZ NZ700732A patent/NZ700732A/en not_active IP Right Cessation
- 2011-05-10 PE PE2012002146A patent/PE20130657A1/es not_active Application Discontinuation
- 2011-05-10 ES ES201290081A patent/ES2408343B2/es not_active Expired - Fee Related
- 2011-05-10 WO PCT/EP2011/057566 patent/WO2011141488A2/en active Application Filing
- 2011-05-10 EA EA201291211A patent/EA201291211A1/ru unknown
- 2011-05-10 DE DE112011101605T patent/DE112011101605T5/de not_active Withdrawn
- 2011-05-10 NZ NZ603497A patent/NZ603497A/en not_active IP Right Cessation
- 2011-05-10 KR KR1020157004528A patent/KR101858797B1/ko active IP Right Grant
- 2011-05-10 MX MX2012013119A patent/MX347105B/es active IP Right Grant
- 2011-05-10 SG SG2012075040A patent/SG184523A1/en unknown
- 2011-05-10 AP AP2012006606A patent/AP3441A/xx active
- 2011-05-10 AR ARP110101621A patent/AR083150A1/es unknown
- 2011-05-10 SE SE1251371A patent/SE1251371A1/sv not_active Application Discontinuation
- 2011-05-10 TW TW103137424A patent/TWI590835B/zh not_active IP Right Cessation
- 2011-05-10 KR KR1020127029438A patent/KR20130030260A/ko not_active Application Discontinuation
- 2011-05-10 GB GB1219275.3A patent/GB2492037A/en not_active Withdrawn
- 2011-05-10 BR BR112012028773A patent/BR112012028773A2/pt not_active Application Discontinuation
- 2011-05-10 CH CH02357/12A patent/CH705273B1/de not_active IP Right Cessation
- 2011-05-10 CN CN2011800231922A patent/CN102946870A/zh active Pending
- 2011-05-10 US US13/697,197 patent/US9700508B2/en active Active
- 2011-05-10 MY MYPI2012004553A patent/MY157673A/en unknown
- 2011-05-10 CN CN201610284534.0A patent/CN105832687A/zh active Pending
- 2011-05-10 EP EP11718747.6A patent/EP2568967B2/en active Active
- 2011-05-10 TW TW100116427A patent/TWI483748B/zh not_active IP Right Cessation
- 2011-05-10 AU AU2011252039A patent/AU2011252039B2/en not_active Ceased
- 2011-10-05 UA UAA201212796A patent/UA106278C2/uk unknown
2012
- 2012-10-08 EC ECSP12012236 patent/ECSP12012236A/es unknown
- 2012-10-09 TN TNP2012000488A patent/TN2012000488A1/en unknown
- 2012-10-10 ZA ZA2012/07603A patent/ZA201207603B/en unknown
- 2012-10-22 NI NI201200157A patent/NI201200157A/es unknown
- 2012-10-26 CL CL2012003012A patent/CL2012003012A1/es unknown
- 2012-10-29 CR CR20120549A patent/CR20120549A/es unknown
- 2012-10-30 IL IL222772A patent/IL222772B/en not_active IP Right Cessation
- 2012-11-05 DK DKPA201270677A patent/DK178741B1/da not_active IP Right Cessation
- 2012-11-08 CO CO12201488A patent/CO6640216A2/es unknown
- 2012-11-09 GT GT201200304A patent/GT201200304A/es unknown
- 2012-11-26 NO NO20121414A patent/NO20121414A1/no not_active Application Discontinuation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4457933A (en) *	1980-01-24	1984-07-03	Bristol-Myers Company	Prevention of analgesic abuse
US20060039970A1 (en) *	2000-02-08	2006-02-23	Benjamin Oshlack	Tamper-resistant oral opioid agonist formulations
WO2003013525A1 (en) *	2001-08-06	2003-02-20	Euro-Celtique S.A.	Opioid agonist formulations with releasable and sequestered antagonist
US20070014732A1 (en) *	2001-08-06	2007-01-18	Purdue Pharma L.P.	Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant agent
WO2010140007A2 (en) *	2009-06-05	2010-12-09	Euro-Celtique S.A.	Dosage form

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
OLIVETO ALISON H ET AL: "Hydromorphone-naloxone combinations in opioid-dependent humans under a naloxone novel-response discrimination procedure" EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY, vol. 6, no. 2, May 1998 (1998-05), pages 169-178 *

Also Published As

Publication number	Publication date
TWI590835B (zh)	2017-07-11
WO2011141488A2 (en)	2011-11-17
EP2568967B2 (en)	2022-07-27
JP5671609B2 (ja)	2015-02-18
EA201291211A1 (ru)	2013-05-30
US9700508B2 (en)	2017-07-11
CA2739751C (en)	2014-08-12
TN2012000488A1 (en)	2014-04-01
GT201200304A (es)	2014-06-09
WO2011141488A3 (en)	2012-04-05
CN105832687A (zh)	2016-08-10
UA106278C2 (uk)	2014-08-11
ECSP12012236A (es)	2013-02-28
ZA201207603B (en)	2014-12-23
ES2408343B2 (es)	2014-07-17
MX347105B (es)	2017-04-12
AU2011252039A1 (en)	2012-11-08
CN102946870A (zh)	2013-02-27
TWI483748B (zh)	2015-05-11
IL222772A0 (en)	2012-12-31
NI201200157A (es)	2013-02-05
CA2739751A1 (en)	2011-11-10
KR101858797B1 (ko)	2018-05-16
GB201219275D0 (en)	2012-12-12
TW201206501A (en)	2012-02-16
DK201270677A (en)	2012-11-05
NZ603497A (en)	2015-02-27
CO6640216A2 (es)	2013-03-22
AP2012006606A0 (en)	2012-12-31
MX2012013119A (es)	2013-02-11
CH705273B1 (de)	2016-06-15
BR112012028773A2 (pt)	2016-07-19
DE112011101605T5 (de)	2013-04-25
ES2408343A2 (es)	2013-06-20
US20130178492A1 (en)	2013-07-11
AU2011252039B2 (en)	2014-06-12
KR20130030260A (ko)	2013-03-26
AR083150A1 (es)	2013-02-06
EP2568967A2 (en)	2013-03-20
NZ700732A (en)	2015-08-28
EP2568967B1 (en)	2018-10-24
KR20150028367A (ko)	2015-03-13
SG184523A1 (en)	2012-11-29
GB2492037A (en)	2012-12-19
DK178741B1 (da)	2016-12-19
IL222772B (en)	2018-11-29
JP2013526508A (ja)	2013-06-24
ES2408343R1 (es)	2013-08-28
CL2012003012A1 (es)	2014-02-21
SE1251371A1 (sv)	2012-12-27
CR20120549A (es)	2013-03-08
PE20130657A1 (es)	2013-06-15
TW201503913A (zh)	2015-02-01
NO20121414A1 (no)	2013-02-11
MY157673A (en)	2016-07-15

Publication	Publication Date	Title
IL253870B (en)	2018-05-31	Certain amino-pyrimidines and pharmaceutical preparations containing them
HRP20182124T1 (hr)	2019-03-08	Farmaceutski sastavi s trenutnim oslobađanjem koji sadrže oksikodon i nalokson
ZA201301419B (en)	2014-07-30	Pharmaceutical composition and administrations thereof
HK1210042A1 (en)	2016-04-15	Pharmaceutical compositions comprising hydromorphone and naloxone
AP3441A (en)	2015-10-31	Pharmaceutical compositions comprising hydromorphone and naloxone
HK1206360A1 (en)	2016-01-08	(aza)indolizine derivative and pharmaceutical use thereof ()
GB2486567B (en)	2014-09-10	Pharmaceutical formulation
PT2521445T (pt)	2019-12-05	Formulação e utilização da mesma
HK1182093A1 (zh)	2013-11-22	生物鹼氨基酯衍生物及其藥物組合物
IL221087A (en)	2015-07-30	Pharmacy or nutritional composition
IL226554A (en)	2017-12-31	Medicinal preparations containing alisporiovir
HRP20141173T1 (hr)	2015-01-30	Medikament koji sadrži miramistin
IL223707A0 (en)	2013-03-05	N-hydroxyformamide derivative and medicament containing same
PT2611445T (pt)	2018-10-24	Composições de buprenorfina de dose elevada e utilização como analgésico
GB201002451D0 (en)	2010-03-31	Pharmaceutical comopitions and devices
EP2657236A4 (en)	2014-02-26	NEW 2-ALKYNYL-N9-PROPARGYLADENINE AND ITS MEDICAL USE
GB201012660D0 (en)	2010-09-15	Inhaler and formulation
GB201003741D0 (en)	2010-04-21	Methods and therapeutic compositions